Tor‐Einar Svae

Biochemical quality of the pharmaceutically licensed plasma OctaplasLG^® after implementation of a novel prion protein (PrP^Sc) removal technology and reduction of the solvent/detergent (S/D) process time

Andrea Heger, Tor‐Einar Svae, Andrea Neisser‐Svae et al. · Vox Sanguinis · 2009 · 58 citations

Pharmacy, Biochemistry, Pharmaceutical Analysis +14

Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate®)

M. Stadler, Gerhard Grüber, Christoph Kannicht et al. · Biologicals · 2006 · 43 citations

Life Sciences, Microbiology, Virology +11

Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)‐treated plasma OctaplasLG^®

Andrea Neisser‐Svae, Andrew Bailey, Luisa Gregori et al. · Vox Sanguinis · 2009 · 39 citations

Pharmacy, Biochemistry, Pharmaceutics +17

Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48h after thawing

Andrea Heger, Jürgen Römisch, Tor‐Einar Svae · Transfusion and Apheresis Science · 2005 · 34 citations

Natural Sciences, Biochemistry, Transport Phenomena +9

A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment

Andrea Heger, Jürgen Römisch, Tor‐Einar Svae · Transfusion and Apheresis Science · 2006 · 31 citations

Medicine, Biochemistry, Pharmaceutics +14